JGC
CAPR icon

J. Goldman & Co’s Capricor Therapeutics CAPR Stock Holding History

J. Goldman & Co’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867K Buy
36,000
+16,000
+80% +$485K 0.02% 482
2026
Q1 		$608K Sell
20,000
-257,900
-93% -$6.87M 0.02% 485
2025
Q4 		$8.02M Buy
277,900
+142,900
+106% +$1.87M 0.21% 133
2025
Q3 		$973K Buy
+135,000
New +$994K 0.02% 336

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

J. Goldman & Co's CAPR Position: Q2 2026 in Review

J. Goldman & Co reduced its Capricor Therapeutics (CAPR) stake by 21% in Q2 2026, selling an estimated $3.46M and leaving 427,321 shares worth $10.3M. The position accounts for 0.27% of the portfolio, ranked #101.

J. Goldman & Co first reported a position in CAPR in Q3 2025 and has held it in 4 quarters since. The position peaked at $17.2M in Q4 2025. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • J. Goldman & Co held 427,321 shares of Capricor Therapeutics worth $10.3M as of Q2 2026.
  • J. Goldman & Co sold 114,201 Capricor Therapeutics shares in Q2 2026, an estimated $3.46M.
  • Capricor Therapeutics made up 0.27% of J. Goldman & Co's portfolio in Q2 2026, its #101 holding.
  • J. Goldman & Co first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • J. Goldman & Co's Capricor Therapeutics position peaked at $17.2M in Q4 2025.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.